# A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

> **NCT02788058** · PHASE2 · UNKNOWN · sponsor: **First People's Hospital of Hangzhou** · enrollment: 76 (estimated)

## Conditions studied

- Lung Adenocarcinoma
- EGFR Positive Non-small Cell Lung Cancer

## Interventions

- **DRUG:** EGFR-TKI
- **RADIATION:** Thoracic Hypofractionated Radiotherapy

## Key facts

- **NCT ID:** NCT02788058
- **Lead sponsor:** First People's Hospital of Hangzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2021-05
- **Final completion:** 2022-05
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2016-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02788058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02788058, "A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02788058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*